ADPKD Clinical Trial
Official title:
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive formation of renal cysts which ultimately lead to a loss of renal function. Tolvaptan (a V2R antagonist) is currently the only effective treatment for preserving renal function in ADPKD. However, side-effects such as polyuria limit its tolerability and thereby the therapeutic potential. This study will test whether co-administration with hydochlorothiazide can improve V2RA efficacy (slowing kidney function decline) and tolerability (quality of life) in ADPKD. Approximately 300 patients will be enrolled.
Aims: The main objectives of the current study are to prospectively test whether HCT co-treatment can improve V2RA efficacy (slowing kidney function decline) and tolerability (quality of life) in PKD. Study design: Investigator driven randomized placebo-controlled multicenter trial Study population: 300 ADPKD patients of ≥18 years, with an eGFR of > 25 mL/min/1.73m2, on stable treatment with the highest tolerated dose of V2RA Intervention: Oral HCT 25 mg once daily or matching placebo for a total of 156 weeks. The randomization ratio will be 1:1. Study visit schedule: study measurements will be performed during 12-weekly visits (which is routine care for V2RA treated patients), except for one additional study visit (or telephone call) 2 weeks after the start of treatment Primary study outcome: Slope of kidney function decline (measured by eGFR) ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04310319 -
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
|
N/A | |
| Completed |
NCT02776241 -
Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
| Terminated |
NCT04152837 -
Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
| Completed |
NCT03717883 -
ADPKD Alterations in Hepatic Transporter Function
|
||
| Recruiting |
NCT05014178 -
Kidney Sodium Functional Imaging
|
||
| Recruiting |
NCT05521191 -
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1 | |
| Terminated |
NCT04064346 -
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
| Completed |
NCT03203642 -
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
|
Phase 2 | |
| Recruiting |
NCT04338048 -
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study
|
||
| Not yet recruiting |
NCT06100133 -
Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?
|
Phase 2 | |
| Completed |
NCT01632605 -
The Vienna RAP Pilot Study
|
N/A | |
| Terminated |
NCT03918447 -
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
|
Phase 3 | |
| Recruiting |
NCT06085807 -
Genetic Testing in Autosomal Dominant Polycystic Kidney Disease
|
||
| Completed |
NCT01853553 -
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 3 | |
| Completed |
NCT04472624 -
Short Term Induction of Ketosis in PKD
|
N/A | |
| Not yet recruiting |
NCT03764605 -
Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
| Completed |
NCT04680780 -
Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
N/A | |
| Completed |
NCT02161068 -
Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping
|
||
| Active, not recruiting |
NCT03273413 -
Statin Therapy in Patients With Early Stage ADPKD
|
Phase 4 | |
| Completed |
NCT00345137 -
Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis
|
Phase 1 |